The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | REZILIENT1: zipalertinib in pre-treated EGFR exon 20 insertion-mutant NSCLC
Marcelo Corassa, MD, A.C. Camargo Cancer Center, São Paulo, Brazil, discusses the Phase IIb REZILIENT1 trial (NCT04036682) of zipalertinib in patients with advanced EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy, with or without prior amivantamab. Zipalertinib demonstrated meaningful clinical activity and durable responses across treatment cohorts. The safety profile was manageable, with mostly low-grade adverse events. These findings support zipalertinib as a promising oral therapy option in this molecularly defined population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Zipalertinib is a new drug that we have as a TKI against EGFR-X121 insertions. Right now we just have amivantimab plus chemotherapy in first line and amivantimab in second line for these patients. And actually, it’s an amivantimab because it’s very toxic and we always say that amivantimab has a manageable side effect profile but it’s quite toxic. So having the option of using a drug, an oral drug, it’s something very interesting...
Zipalertinib is a new drug that we have as a TKI against EGFR-X121 insertions. Right now we just have amivantimab plus chemotherapy in first line and amivantimab in second line for these patients. And actually, it’s an amivantimab because it’s very toxic and we always say that amivantimab has a manageable side effect profile but it’s quite toxic. So having the option of using a drug, an oral drug, it’s something very interesting. It’s a second-line trial actually. It’s a second-line trial that was not compared to anything. So it’s just zipalertinib for patients that had progression on platinum-based chemotherapy and or amivantimab. And we got some very interesting story there. We got like 60% response rates. We got patients that were receiving the drug for maybe less than 10 months. This for a pre-treated population this is quite interesting so I’m not here to discuss well there’s not there’s no comparison here so there’s no hazard ratios and we cannot draw conclusions to say which way is better but I think this is a very good way of thinking that with a high response rate a manageable side effect profile and think it’s much more manageable than we have for instance with the amivantimab rash which is the most important thing we have like 78% of patients with any monotherapy having it instead we have 30% Well, we have some other bad stuff like dry skin, diarrhea and diarrhea maybe is the worst problem here, but it’s manageable. I do not like the word manageable because well, it’s manageable, but it’s not with you. But manageable is just because it’s much easier for you to just use an anti-diarrhea agent and have a good life with it. So I think it’s going to be an option. We have trials and first line right now going on and we have the Resilient 3, the Wukong 28 and deferment with some fulzartanib, fulminatinib and zipalertinib of course. And we are waiting on the results. I really do hope that this could be a very interesting first line option for patients instead of just giving chemo-amivantimab to everyone.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Employment – No Relationships to Disclose
Leadership – No Relationships to Disclose
Stock and Other Ownership Interests – No Relationships to Disclose
Honoraria – Amgen; AstraZeneca; Bristol-Myers Squibb Brazil; Janssen; Lilly; MSD; Novartis; Pfizer; Sanofi/Regeneron; Takeda
Consulting or Advisory Role – AstraZeneca; Bristol-Myers Squibb; Takeda
Speakers’ Bureau – AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Takeda
Research Funding – No Relationships to Disclose
Patents, Royalties, Other Intellectual Property – No Relationships to Disclose
Expert Testimony – No Relationships to Disclose
Travel, Accommodations, Expenses – MSD
